La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Nanexa Bilan de santé

Santé financière contrôle des critères 4/6

Nanexa possède un total de capitaux propres de SEK93.0M et une dette totale de SEK1.8M, ce qui porte son ratio d'endettement à 2%. Son actif total et son passif total sont SEK123.9M et de SEK30.9M.

Informations clés

2.0%

Ratio d'endettement

SEK 1.83m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	SEK 47.84m
Fonds propres	SEK 93.01m
Total du passif	SEK 30.90m
Total des actifs	SEK 123.91m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

How Much Does Nanexa's (STO:NANEXA) CEO Make?

Dec 09

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de NANEXA ( SEK62.3M ) dépassent ses passifs à court terme ( SEK29.1M ).

Passif à long terme: Les actifs à court terme de NANEXA ( SEK62.3M ) dépassent ses passifs à long terme ( SEK1.8M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: NANEXA dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de NANEXA a été réduit de 13.5% à 2% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: NANEXA dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: NANEXA dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 26.7 % chaque année

Nanexa Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Nanexa's Phase I Trial of NEX-22 in Type 2- Diabetes Progresses with Next Dose Group According to Plan

Nanexa AB (publ) Announces Chief Financial Officer Changes

Nanexa AB (Publ) Announces That First Patient Dosed in Nanexa's Phase I Trial of NEX-22 in Type 2 Diabetes

New major risk - Financial position

Nanexa AB Receives Approval for NEX-22 Clinical Study

Nanexa AB (publ) Elects Hanna Tilus as Members of the Board

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.14 loss in 1Q 2023)

Nanexa AB (publ) Announces Approval of Clinical Trial Application for NEX-22 Study Delayed

New major risk - Shareholder dilution

Full year 2023 earnings released: kr1.09 loss per share (vs kr1.16 loss in FY 2022)

Nanexa AB (publ), Annual General Meeting, May 15, 2024

Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA

Consensus revenue estimates increase by 32%

New minor risk - Financial position

Third quarter 2023 earnings released: kr0.11 loss per share (vs kr0.24 loss in 3Q 2022)

Nanexa AB Completes Clinical Phase I Study with NEX-20

Consensus EPS estimates upgraded to kr0.42 loss

Price target decreased by 19% to kr4.95

Second quarter 2023 earnings released: kr0.16 loss per share (vs kr0.32 loss in 2Q 2022)

Nanexa AB Confirms Continued Positive Results from A New Preclinical Study of Nex-22

Nanexa AB (Publ) Approves Election of Jakob Dynnes Hansen as Member of the Board

Nanexa AB (Publ) Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election

First quarter 2023 earnings released: kr0.14 loss per share (vs kr0.24 loss in 1Q 2022)

Nanexa AB (publ) to Report Q1, 2023 Results on May 04, 2023

Full year 2022 earnings released: kr1.16 loss per share (vs kr1.01 loss in FY 2021)

Nanexa AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Nanexa Starts the Phase 1 Study of NEX-20 According to Plan

Price target decreased to kr6.00

No longer forecast to breakeven

Nanexa Receives Approval to Start Clinical Trial with NEX-20

Third quarter 2022 earnings released: kr0.24 loss per share (vs kr0.18 loss in 3Q 2021)

Nanexa AB (Publ) and Vitrivax, Inc Reach Agreement in Principle

Nanexa AB (Publ) Launches NEX-22 Product Project to Address Huge Market

Nanexa AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Second quarter 2022 earnings released: kr0.32 loss per share (vs kr0.33 loss in 2Q 2021)

Nanexa AB (publ) Receives Extended GMP-Certificate for the New Pilot Plant

Less than half of directors are independent

Nanexa AB (publ), Annual General Meeting, Jun 09, 2022

Nanexa Receives Grant from VINNOVA for Study with Monoclonal Antibodies

Forecast to breakeven in 2023

Price target decreased to kr7.00

Full year 2021 earnings: EPS and revenues miss analyst expectations

Nanexa AB Announces That the Company's Preclinical Investigation

Price target decreased to kr7.00

High number of new directors

Nanexa Announces Inclusion of Patients in its Phase I Study with NEX-18

Second quarter 2021 earnings released

First quarter 2021 earnings released: kr0.29 loss per share (vs kr0.22 loss in 1Q 2020)

Nanexa Appoints Jonas Fransson as Head of Pharmaceutical Development

New 90-day low: kr10.20

Full year 2020 earnings released: kr1.09 loss per share (vs kr0.88 loss in FY 2019)

Nanexa AB to Report Q1, 2021 Results on May 06, 2021

How Much Does Nanexa's (STO:NANEXA) CEO Make?

New 90-day low: kr10.25

Third quarter 2020 earnings released: kr0.18 loss per share

New 90-day high: kr13.40

New 90-day high - kr13.35

First half earnings released

New 90-day high - kr11.80

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines